title: Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy.
abstract: Clinical characteristics and risk factors of hand-foot syndrome were investigated in patients who received capecitabine-containing chemotherapy. Toxicity data were analyzed from 179 patients in 4 prospective clinical trials testing docetaxel/capecitabine/cisplatin in stomach cancer, capecitabine/cisplatin in biliary or stomach cancer, and vinorelbine/capecitabine in breast cancer. Hand-foot syndrome was reported in 116/179 (64.8%) of patients, with grade 3 hand-foot syndrome in 8/179 (4.5%). Hand-foot syndrome first developed within the first 3 chemotherapy cycles in 100/116 (86.2%) patients, with the median onset for all 3 treatment regimens occurring during cycle 2. Because severe reactions were rare, hand-foot syndrome was not a major factor influencing treatment schedule. Risk factor analyses showed that combined use of docetaxel and preceding chemotherapy-related stomatitis were significant risk factors for the development of hand-foot syndrome. Our results suggest that a combined treatment agent and a patient's susceptibility to chemotherapy-related toxicity may increase the risk of capecitabine-induced hand-foot syndrome.
authors.affiliation: Department of Pharmacy, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
authors.forename: Young Seol
authors.initials: YS
authors.lastname: Heo
authors.forename: Heung Moon
authors.initials: HM
authors.lastname: Chang
authors.forename: Tae Won
authors.initials: TW
authors.lastname: Kim
authors.forename: Min-Hee
authors.initials: MH
authors.lastname: Ryu
authors.forename: Jin-Hee
authors.initials: JH
authors.lastname: Ahn
authors.forename: Sung Bae
authors.initials: SB
authors.lastname: Kim
authors.forename: Jung Shin
authors.initials: JS
authors.lastname: Lee
authors.forename: Woo Kun
authors.initials: WK
authors.lastname: Kim
authors.forename: Hye Kyung
authors.initials: HK
authors.lastname: Cho
authors.forename: Yoon-Koo
authors.initials: YK
authors.lastname: Kang
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D000069287:Capecitabine; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003841:Deoxycytidine / Q000009:adverse effects* / Q000031:analogs & derivatives*; D004359:Drug Therapy, Combination; D004890:Erythema / Q000139:chemically induced* / Q000473:pathology; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives; D005528:Foot / Q000473:pathology*; D006225:Hand / Q000473:pathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D012307:Risk Factors; D013577:Syndrome
chemical_list: D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil